Zobrazeno 1 - 10
of 43
pro vyhledávání: '"35"'
Autor:
Michael S. Simon, Yani Lu, Jane Sullivan-Halley, Michael F. Press, Brian L. Strom, Leslie Bernstein, Kathleen E. Malone, Huiyan Ma, Dennis Deapen
Publikováno v:
Cancer Research. 72:3590-3590
Purpose: To evaluate the extent to which the black-white disparity in mortality following breast cancer diagnosis is explained by the expression status of four biomarkers - estrogen receptor (ER), progesterone receptor (PR), human epidermal growth fa
Autor:
Patricia A. Thompson, Michelle Turner, Carolyn Mies, Jules Cohen, Caterina Vacchi-Suzzi, Alison Stopeck, Lea N. Baer, Christina Preece, Christy A. Russell, Rebecca Batiste, Julie Anne L Gemmill
Publikováno v:
Cancer Research. 81:PS5-37
Background: Identifying when to start CDK4/6 inhibitors or use chemotherapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) remains challenging. The 21-gene Oncotype DX Breast Recurrence Score® test is validated to predict chemothe
Autor:
Natacha Duquette, Alain Zgheib, Jean-Christophe Currie, Alain Larocque, Michel Demeule, Cyndia Charfi, Christian Marsolais, Richard Béliveau, Borhane Annabi
Publikováno v:
Cancer Research. 80:2910-2910
Rational: Breast cancers are comprised of several subtypes that share similar clinicopathological features, but that also exhibit several different biological characteristics. Triple-negative breast cancer (TNBC), which comprises 10-20% of breast can
Publikováno v:
Cancer Research. 75:P6-10
Background More than 70% of breast cancer patients develop endocrine-responsive disease with estrogen receptor (ER)-positive or progesterone receptor-positive tumors or both [1] and require endocrine treatment with either estrogen blockage or ablatio
Autor:
Ronald Linnartz, Shawnt Issakhanian, Karen A. McDonald, Richard S. Finn, S Hurvitz, Emmanuelle DiTomaso, NA O'Brien, Luo Tong, Raul Ayala, DJ Slamon, S Hirawat
Publikováno v:
Cancer Research. 73:PD1-5
Background: The selective mTORC1 inhibitor everolimus (RAD001/Affinitor®) has recently been approved, in combination with exemestane, for treatment of advanced hormone receptor positive breast cancer after demonstrating significantly improved progre
Autor:
C-Y Shiau, Y-L Wang, C-H Tzeng, J-H Chiu, L-M Tseng, K-L King, Y-M Shyr, Y.-F. Tsai, M-H Hung, T-C Chao, C-Y Liu
Publikováno v:
Cancer Research. 72:P3-12
Purpose: Biological subtypes and age were well-known risk factors associated with the development of brain metastasis in breast cancer patients. However the impact of each biological subtype in different age group was less discussed. Patient and meth
Autor:
Omer Diker, Recep Ak, Berna Oksuzoglu, Deniz Can Guven, Neyran Kertmen, Polat Olgun, Hakan Taban, Onur Bas, Bahadir Koylu, Burak Yasin Aktas, Sercan Aksoy
Publikováno v:
Cancer Research. 81:PS10-52
BackgroundInvasive breast cancers are characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) approximately 15 to 25%. Survival outcomes was improved after introduction of Trastuzumab treatment. Trastuz
Autor:
Gloria Broadwater, Susan Dent, Gretchen Kimmick, Kevin C. Oeffinger, Michel G. Khouri, Sanjeev Balu, Terry Hyslop
Publikováno v:
Cancer Research. 81:PS10-48
Background: CDK 4/6 inhibitors in patients (pts) with HR+/HER2- ABC has led to significant improvements in clinical outcomes, however our understanding of the impact of these treatments on CV health is unknown. Gains in overall survival should not be
Publikováno v:
Cancer Research. 75:P1-01
Purpose: The aim of the study is to evaluate the efficacy of preoperative breast MRI in T1-2 women with breast cancer. Methods: Total 1179 patients, who had T1-2 breast cancer and underwent definitive surgery between 2007 and 2010, were reviewed in t
Publikováno v:
Cancer Research. 80:P4-10
Background:In the United States, more than 3 million women are affected by BC and approximately 41,760 women are expected to die from it in 2019. Although improvements have been made in the past decades, there is still a strong need for the developme